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1. Introduction
Schistosomiasis is a chronic water-borne infection caused by digenetic trematodes that be‐
long to the genus Schistosoma. There are two main forms of the disease namely; urinary and
intestinal schistosomiasis. The major aetiologic agents of the intestinal form are Schistosoma
mansoni and Schistosoma japonicum. The less common species that have also been associated
with intestinal disease are Schistosoma mekongi, Schistosoma guineensis and the related species
Schistosoma intercalatum. Schistosoma haematobium is the only known agent of urogenital
schistosomiasis [1]. S. haematobium and S. mansoni infections have been widely reported in
all parts of Nigeria although the former predominates [2].
Schistosomiasis  is  transmitted by snails.  Each of  the species is  transmitted by a snail  of
a  different  species.  The  intermediate  host  of  S.  haematobium  is  a  fresh  water  snail  be‐
longing  to  the  genus  Bulinus.  It  is  a  turreted  snail  with  a  left-handed  opening  when
looked at  with the spire  upwards.  Three main species  are  known to harbour the larval
stages of schistosomes [3]:
• The Africanus group (sub-genus Physopsis) which are involved in the transmission of the
disease in eastern, central and west Africa
• The truncatus group (sub-genus Bulinus) which transmits infection in the near East and in
some parts of Africa and
• The forskalli group. This group has been associated with the transmission of urinary
schistosomiasis in Nigeria among other places in Africa.
S. mansoni is transmitted by flattened planorbid snails belonging to the genus Biomphalaria.
Four main groups have been associated with the transmission of intestinal schistosomiasis
in Africa. These include:
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• The Pfeifferi group which are the main vectors in Africa
• The sudanica group which occur in both east and west Africa
• The choanomphala which are found in the great lakes and act as agent in Lake Victoria
and
• The Alexandrina group which occur sporadically in north, east and south Africa [3]
The  intermediate  host  of  S.  japonicum  are  operculated  snails  that  belongs  to  the  genus
Oncomelania.  Important  species  such  as  O.  hupensis,  O.  nosophora,  O.  formosana  and  O.
quadrasi  are  involved  in  the  transmission  of  infection  in  different  areas  of  Asia  where
the infection predominates [3].
The role of water bodies in the transmission of infection cannot be over emphasized [4].
Such water bodies include fresh water streams, water accumulated as a consequence of con‐
struction of dams and irrigation projects and slow flowing or stagnant water. Although, the
main courses of large rivers may not be associated with the transmission of schistosomiasis,
but water sustained by them through seasonal flooding and impoundment may provide
avenues for the sustenance of the snail intermediate host. Water also provides an opportuni‐
ty for the cercariae to survive and penetrate the definitive host. Humans are also pivotal in
the transmission of schistosomiasis. Through insanitary disposal of urine or faeces, water
bodies are contaminated with the eggs of schistosomes. Worldwide, 900 million people do
not have access to an improved water source, while an estimated 2.5 billion, half of all peo‐
ple in developing countries lack access to adequate sanitation [5,6]. In rural and poor agri‐
cultural communities without pipe-borne water, the locals depend on cercariae infested
streams for their economic and recreational needs thereby exposing themselves to infection.
The control of schistosomiasis involves an integrated process directed at the infected sub‐
jects, snail intermediate hosts, environmental modification, health education and the provi‐
sion of pipe-borne water [7]. In this review, the epidemiology, diagnosis and control of
schistosomiasis is examined in details with notes on the factors impeding the control of the
disease in Africa with inferences drawn from the Nigerian experience.
2. Epidemiology of schistosomiasis
Schistosomiasis is estimated to infect about 240 million people worldwide while an esti‐
mated  779  million  people  (more  than  10%  of  the  world  population)  are  at  risk  of  ac‐
quiring infection. Although, the transmission of schistosomiasis has been documented in
77 countries worldwide, only 52 of these countries are endemic for the disease, majority
of which are in the Africa continent.  Forty six [46]  of  these countries are in Africa.  Un‐
like  the  situation  in  Africa,  some countries  in  Latin  America  and Asia  and most  coun‐
tries  of  the  Caribbean  and  the  Middle  East  have  brought  down  the  prevalence  of
schistosomiasis  and prevented severe  morbidity  from the  infection  through a  concerted
public  health effort.  But in many of  these countries,  there are still  endemic regions and
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a  potential  for  resurgence  exists  [8].  About  120  million  people  infected  with  schistoso‐
miasis  are  estimated to  be  symptomatic  while  about  20  million develop severe  disease.
The  disability  adjusted  life  years  due  to  schistosomiasis  is  about  1.7-4.5  million  while
between 150,000  to  280,000  people  are  known to  die  as  a  consequence  of  schistosomia‐
sis  per  year.  Africa accounts  for  85% of  the disease burden [9,10].  Urinay schistosomia‐
sis  has been reported in 38 countries  in Africa.  Annual  mortality due to S.  haematobium
infection in east Africa has been estimated at 1 per 1000 infected adults [11]. In Malawi,
Save  the  children’s  1998  survey  of  schoolchildren  in  Mangochi  found  that  the  overall
prevalence  of  schistosomiasis  in  coastal  and  upland  schools  was  36%.  In  some  of  the
schools,  the  prevalence  was  as  high as  87% [12].  In  a  related study in  Cameroon,  Mba
and  Useh  [13]  reported  urinary  schistosomiasis  among  39.2%  of  the  subjects  studied.
Mixed infection of  S.  haematobium  and S.  mansoni  occurred in  4.5% of  the  subjects.  The
number of  infected subjects  treated for the disease using praziquantel  rose for 12.4 mil‐
lion in 2006 to 33.5 million in 2010.  It  is  estimated that  90% of those that  require treat‐
ment live in Africa.  This implies that over 60% of people suffering from schistosomiasis
particularly in Africa are not able to procure treatment or have access to treatment due
to the relatively high cost of praziquantel.
2.1. Schistosomiasis situation in Nigeria
It is estimated that 30 million Nigerians are infected with schistosomiasis. When examined
against a projected population of 162 million Nigerians, it becomes clear that over 18.5% of
the populace have schistosomiasis. The problem becomes more glaring when the projected
population of infected people is examined in terms of those who carry the greatest burden
of the disease; in this case, school age children. About 23 years ago, Ejezie et al [2] published
a major review entitled “the schistosomiasis problem in Nigeria” where they highlighted the
embarrassing and increasing endemicity of schistosomiasis without any concrete plan for
control. Not much has changed almost two and half decades after. In another landmark re‐
view on the “Nigerian environment and parasitic infections”, Ejezie [14] noted that “a large
proportion of the people consist of men and women who are ignorant of the rules of basic
hygiene. These people are entrapped by the worst manifestations of poverty, worsened by
infectious tropical diseases, malnutrition, high birth and death rate”. They are, as it were,
caught in the so-called vicious circle-“they are sick because they are poor, they become poor‐
er because they are sick and sicker because they are poorer” [15]. The problem seems to
have grown worst. In the above publication, infection with S. haematobium was reported in
all the regions in Nigeria with a prevalence as high as 60-75% among schoolchildren in some
communities. The endemicity of S mansoni was also reported though not as wide spread as
the former. Perhaps this report and others encouraged the government of Nigeria to consti‐
tute the ‘National Schistosomiasis Control Committee”. Regrettably, this Committee only
existed on paper as funds were not made available to organize operational research to delin‐
eate endemic communities for treatment.
The morbidity of schistosomiasis in Nigeria reflects what has been published for endemic
countries in Africa and Asia. Infection predominates in schoolchildren aged between 5-19
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years and thereby decline following the typical “age verus prevalence/intensity convex
curve”. An earlier study conducted on urinary schistosomiasis reported a prevalence of
45.4% in Ilorin, Central Nigeria with 25.9% of infected subjects excreting 1,000eggs/10ml
urine [16]. In a related study in Adim community located in south south Nigeria, this author
and his colleagues reported an overall prevalence of 53.8% with males and females account‐
ing for 53.8% and 53.9% of infection respectively. In this study, the mean haematuria, protei‐
nuria and egg-output were 23.19 ery/ul, 49.9mg/100ml and 37.3 eggs/10ml urine [17]. Three
years after, in the absence of a control programme, the prevalence of urinary schistosomiasis
in this same community rose astronomically to 90.7% among children out of the school sys‐
tem while those who attended school had a prevalence of 86.8% [18].
The current picture of schistosomiasis endemicity in Nigeria is very worrisome. For instance
in their investigation on urinary schistosomiasis around Oyan Reservoir, south west Niger‐
ia, Akinwale et al [19] reported a prevalence that ranged from 20.39%-83.9% in some com‐
munities around the reservoir. In Bida, north central Nigeria, Banji et al [20] reported a
prevalence of 28% among school children. Recently, Goselle et al [21] reported the endemici‐
ty of S. mansoni in Jos, north central Nigeria. Yet another study reported on the epidemiolo‐
gy of schistosomiasis in six local government areas in Plateau State, Nigeria [22]. The overall
prevalence of infection was 47.8%. Many water bodies in the study communities were colon‐
ized by infected Bulinus snails. Snail infection rates varied significantly (P<0.001) between
the dry and wet seasons. Most studies on schistosomiasis are based on the school system.
Not much has been done on children out of the school system and on preschool children. In
one of such studies among preschool children in a rural community near Abeokuta, south
west Nigeria, Ekpo et al [23] reported a prevalence of 58.1% with the overall geometric egg
count of 1.17 eggs/10ml urine. There is gross lack of work on genital schistosomiasis in Ni‐
geria. With a high prevalence of HIV/AIDS infection in Nigeria, it is important that this be
addressed. Genital schistosomiasis particularly in women may have helped to spread the
transmission of HIV infection.
2.1.1. Consequences of schistosomiasis infection in Nigeria
The pathology associated with schistosomiasis in Nigeria is consistent with what have been
reported in other endemic countries. The pathology of schistosomiasis is essentially a series
of chronic inflammatory lesions produced in and around blood vessels by eggs which may
be found lodged in practically any viscera or their products and sometimes by dead worms.
There are comprehensive studies in the literature on the pathology due to urinary schistoso‐
miasis [24,25,26,27]. In summary disorders such as cercarial dermatitis, haematuria, protei‐
nuria, calcification of bladder, uteric stricture and dilatation, hydronephrosis and squamous
cell carcinoma have been reported. Others include multi granulomatas in the bladder and
vesicle calculus. Attah [28] noted that the pathology of intestinal schistosomiasis is charac‐
terized by the presence of a small superficial ulceration of colonic mucosa, with eggs and
granulomas found much more frequently in the serosa than in the mucosa; and by lesions
which are secondary to disintegration of eggs and aggravated by oviposition. Hepatic le‐
sions is marked by eosinophilic infiltration of the portal tract with or without eggs. In chron‐
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ic cases, the major lesion in the liver is ‘pipe stem fibrosis’, an enlarged liver and fibrosed
portal tract with a varying degree of portal vein destruction.
Schistosomal  infection  has  been  associated  with  other  negative  effects  among  Nigerian
children.  These  include  poor  attendance  at  school,  low  cognitive  ability,  educational
achievement  and  malnutrition.  This  is  exemplified  in  one  study  in  which  we  treated
schoolchildren  with  urinary  schistosomiasis  with  PZQ and monitor  its  effect  on  educa‐
tional  attainment  in  Adim community  of  Nigeria.  The  pass  rate  among  the  cohort  im‐
proved  following  the  first  treatment  session  from  81.4%  to  90.7%,  latter  declined  to
84.2% following the  second treatment  session  but  the  net  improvement  in  performance
was  statistically  significant  [29].  On  the  contrary,  Ejezie  and  Ade-Serrano  [30]  showed
that  anthropometric  measurements  in  relation  to  age,  to  average  marks  scored  and
school  attendance were  not  found to  bear  any relationship to  the  intensity  of  S.  haema‐
tobium  infection in  Lagos  Nigeria.  Similarly,  Ekanem et  al  [31]  did not  find any signifi‐
cant  impact  of  infection on anthropometric  parameters,  school  attendance and academic
performance among infected children compared to controls in Nigeria. In Kenya, Corbet
et  al  [32]  showed  that  intensity  of  S  mansoni  infection  correlated  with  hepatomegaly,
which  was  more  clearly  related  to  nutritional  status.  Furthermore  they  noted  that  chil‐
dren  with  hepatomegaly  were  significantly  more  stunted  and/or  wasted  than  those
without,  and  had  less  variety  in  their  diet.  Similarly,  Stephenson  et  al  [33,34]  demon‐
strated  that  children  infected  with  S.  haematobium  had evidence  of  poor  nutritional  sta‐
tus,  with improved growth rates  in  children and weight  gain in undernourished adults
following  treatment  with  metrifonate  or  PZQ.  The  consequences  of  infection  may  be  a
function  of  the  morbidity  of  infection  in  the  area,  age,  nutritional  and economic  status
of the infected subjects.
Educational
Performance
Pre-Treatment
N=210
Post-treatment 1
N=183
Post-treatment 11
N=203
X2 P
Total attendance
Pupils days
46,902 40,269 40,402
Attendance rate
(%)
86.7 81.5 81.1 2.99 0.22
Days school open 257 270 245
No passed 171 166 171
Pass rate 81.4 90.7 84.2 7.2 0.027
Adopted from Meremikwu et al (2000)
Table 1. Effect of treatment on attendance and pass rate in a cohort of school children over three years
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3. Diagnosis of schistosomiasis
Diagnosis is pivotal in all aspects of the control of schistosomiasis. Feldmeier et al [35] noted
that decisions on individual and community treatment, estimations on prognosis and as‐
sessment of morbidity, determination of transmission potential, evaluation of treatment and
of control measures all build on the results from diagnostic testing. The diagnosis of human
schistosomiasis is based on a combination of clinical symptoms, history of residence in an
endemic or non-endemic area, parasitological examinations, serological findings and ultra‐
sonography [36]. However all presently available techniques are characterized by diagnostic
imperfections or inaccuracies. Consequently, Feldmeier et al [35] recommended that selec‐
tion and application of methods should be related to information being sought while inter‐
pretation of test results should take cognizance of the drawbacks and constraints associated
with the method being used.
3.1. Clinical diagnosis
The expected clinical conditions include cutaneous lesions, urticaria, eosinophilia and pul‐
monary disorders. Others include haematuria, cystitis, urinary calculi and vesicular disor‐
ders which should be differentiated from other disease conditions giving rise to renal
calculi, nephritis, tuberculosis, haemoglobinuria, benign and malignant papillomata. This
method of diagnosis is not very sensitive and specific. In endemic areas children may not be
able to relay their problem to the physician. On the other hand, primary health care workers
who are the first set of health workers to come in contact with infected subjects may not be
knowledgeable enough to relate this clinical presentation with schistosomiasis.
3.2. Direct parasitological techniques
Urine egg count is one of the three methods for estimating the intensity of infection; the oth‐
er two, tissue egg burden and number of worm pairs, can only be determined at autopsy
[37]. The WHO [38] noted that quantitative egg count provides reliable baseline data for
studies on chemotherapy, malacology, sociology and contamination patterns in defined
communities. In the same vein, it also provides information on the transmission potential of
different population subgroups. Parasite counts are usually estimated by filtration with ny‐
trel, standard filter paper (Whatman) or by centrifugation of urine. The filtration technique
which gives excellent results is applicable in the field [39]. In Africa, filtration with What‐
man filter paper is predominantly used in the field and has been associated with reliable
and consistent results [17,40]. Smith et al [41] reported that in the active stage urinary excre‐
tion can be used as an indirect estimate of tissue egg burden and severity of the disease and
is particularly relevant for epidemiological studies. In the inactive stage of infection, few or
no eggs may be present. Urine egg counts are of limited essence in estimating the prevalence
of severe disease in inactive stage of schistosomal disease or in older population. In a related
study, a significant correlation was found between haematuria, proteinuria, leucocyturia
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and intensity of infection as measured by egg excretion in urine [42]. The best correlation
between the reagent strip findings and the intensity of infection was obtained when the
three parameters were combined. After treatment with metrifonate, the reduction of egg ex‐
cretion was paralleled by the normalization of the reagent strip findings. Analysis of day-to-
day variation demonstrated a similar low variation of the filtration technique and the
reagent strip findings. The authors concluded that polyvalent reagent strips may be a useful
tool for diagnosis of heavily infected patients under field conditions, as they permit rapid
and easy identification of subjects with high egg counts.
Unlike the eggs of S. haematobium, the eggs of S. mansoni, S. japonicum and S. intercataltum are
passed in faeces. The formol ether concentration technique may be used to demonstrate the
spined eggs of any of these parasites. The problem associated with the technique is that it is
not field application. Apart from the requirements of a centrifuge and a microscope, the use
of ether which is highly flammable poses a hazard. The Kato thick smear technique is more
widely used in field work in Africa. The samples can be prepared in the field while exami‐
nation may be done later.
For community-based studies, enormous human and financial resources are expended to es‐
tablish those infected before the administration of chemotherapy. A reasonable number of
skilled manpower would be required to avoid undue waste of time. In practical terms it is
usually not possible to identify infected people the same day and offer them treatment in the
field. In some instances during a re-visit for treatment, infected children may miss treatment
either because of sickness or lending a helping hand to their parents in the farm. Thus a lot
of money that ought to be used to procure treatment is expended on diagnosis. Parasitologi‐
cal confirmation of eggs in urine or stool have been associated with some degree of poor ac‐
curacy and sensitivity [43]. The day-to-day variations in excreted egg counts in individual
patients [44] and the uneven distribution of eggs in excreta [45] and the occurrence of imma‐
ture infections [46] are some of the limiting factors. Others include the immune dependence
of schistosome egg excretion and the survival of worms after an immunological induced in‐
hibition of fecundity [47]. Nonetheless, the establishment of prevalence and morbidity by
the presence of ova is necessary for understanding the epidemiological profile of different
endemic foci.
3.3. Detection of pathology and ultrasonography
The introduction of cytoscopy in 1879 [48] facilitated the visualization of bladder patholo‐
gy as a consequence of S. haematobium infection in vivo. Pyelographic and histopathologi‐
cal  studies  have  been  used  to  assess  urinary  tract  pathology  due  to  S.  haematobium
infection in Nigeria [24,27,49]. Modern radiological techniques have finally provided a va‐
riety of methods for the detection and follow-up of schistosome related morbidity.  Such
procedures  include  various  radiographic  techiques,  isotype  investigations  of  the  kidney
and liver,  computed tomography and more  recently,  ultrasonography [50].  Table  2  is  a
summary comparing S. haematobium-related morbidity with currently available methods of
detecting morbidity.
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CYSTOSCOPY RENAL FUNCTION
TEST
X-RAY COMPUTED
TOMOGRAPHY
SONOGRAPHY
A. BLADDER
Granuloma + - + + +
Sandy Patches + - -/+ + +
Ulcers + - -/+ + -/+
Cystitis + - - -/+ -
Stones + - + + +
Calcification -/+ - + + -/+
Polyps + - + + +
Carcinoma + - + + +
B. URETER
Hydroureter -/+ -/+ + + -/+
Stricture -/+ -/+ + + -
Dilatation/
Distortion
- - + + -
Calcification -/+ - + + -/+
Polyps -/+ - + + -/+
C. KIDNEY
Congestion - -/+ + + +
Hydronephrosis - -/+ + + +
Performance - + + + -
Adopted from Hatz et al [50].
Table 2. Comparison reflects possibility of detecting without rating efficiency and applicability.
3.4. Indirect parasitological techniques
3.4.1. Haematuria and proteinuria
The detection of haematuria and proteinuria is widely used in Nigeria and the rest of endemic
communities in Africa to diagnose urinary schistosomiasis. Haematuria arises when migrating
eggs puncture small capillaries of the viscal plexus to get into the bladder [51]. Haematuria was
the first sign to be associated with schistosomiasis [52] while proteinuria was described later.
Haematuria is usually seen at the end of urination (terminal haematuria), although haematuria
throughout micturition may be seen in some severely infected cases. High levels of urinary pro‐
tein in S. haematobium infection has been linked with nephritis [53], nephritic syndrome [54] and
bladder pathology [55]. Some authors have cited the reversibility of proteinuria after treatment
to support the renal origin of proteinuria [56,57]. It is now generally accepted that bilharzial pro‐
teinuria is of post –renal origin and not a sign of impaired renal function [58].
Several studies have confirmed that the detection of proteinuria and haematuria when used to‐
gether is a better means to measure morbidity than when used separately [25,40,59]. In Lagos,
Nigeria, Ejezie and Ade-Seranno, [40] reported haematuria in 655 of infected children with the
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greatest intensity in patients with the highest egg output. Relatedly, Mottt et al [59] and Tanner
et al [60] noted that all children between 5-14 years with more than 50 eggs per 10ml of urine
had blood in the urine detected by chemical reagent strips. This author and his colleagues test‐
ed the usage of the presence/absence of haematuria and proteinuria in monitoring the out‐
come  of  treatment  of  urinary  schistosomiasis  with  artesunate.  The  mean  ova  count,
haematuria and proteinuria of 87 infected subjects who were treated significantly reduced
from 55.5± 1.3ova/10ml urine, 168.6±1.23 ery/µL and 458.6± 1.4 mg/dl to 1.8±0 ova/10ml urine,
9.1±0.4 ery/µL and 65.4 mg/dl respectively (P<0.05 in all cases). We therefore concluded that re‐
agent strips are reliable in monitoring the efficacy of treatment with artesunate [61].
Reagent strips are cheap, fast, simple and can be readily integrated into the primary health
care programme. But there may be gender bias in females that may lead to under-reporting
or over-reporting (false positives). The contamination of urine with menstrual blood would
yield false positive results for haematuria. A similar finding may be noted for leucocyturia
and proteinuria [62]. The usefulness of a semi-quantitative grading of haematuria as a corre‐
late to intensity of infection has to be questioned in women with schistosomiasis, since the
ectopic localization of eggs in the vagina, cervix or the endometrium may lead to contact
bleeding, intermenstrual bleeding or to bloody discharge [63]. Evidence for false positive re‐
agent strip readings in women has been shown in a population based study on Pemba Is‐
land, Tanzania. A higher prevalence of haematuria readings were observed in women of
child-bearing age than in males of similar age, although intensity of infection and morbidity
as measured by the number of eggs per unit of urine, and as indicated by pathological ultr‐
sonography was significantly less in women than in men [64]. Vester et al [65] reported cul‐
ture-related biases for mass screening with urine analysis strips. About 15% of
schistosomiasis-free Sudanese girls and women circumcised either by the “pharaonic” or the
“sunna” method constantly or intermittently show mild haematuria and/or leucocyturia.
Since female circumcision is practiced not only in Muslim and Coptic societies in the Sudan,
but also in more than 40 ethnic groups in Africa and Arabia [66], false positive reagent strip
readings are expected to occur where this tradition and schistosomiasis overlap.
3.4.2. Rapid Assessment Procedure (RAP) using questionnaires
A greater proportion of money slated for the control of schistosomiasis is usually spent on
diagnosis particularly when eggs are to be counted. The fact that schistosomiasis is focal in
distribution with millions of infected subjects in endemic communities showing different
prevalence and morbidity rates compound the problem. The problem is more felt in Africa
with her lean financial resources but with the largest burden of the disease. The rapid as‐
sessment procedure was conceived to maximize resources in diagnosis which could be di‐
rected to possible chemotherapeutic control of infection
The RAP involves the use of a rapid and inexpensive method to identify communities with a
high prevalence of and morbidity due to urinary schistosomiasis. It is based on using simple
questionnaires to find out how frequent schistosomiasis is in a community [67]. Kroeger [68] and
Ross and Vaughan [69] showed that health interview surveys can be used in both developed and
developing countries to assess morbidity as it is perceived by community members, and to in‐
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vestigate the utilization patterns of health services. Tanner [70] demonstrated that asking the
beneficiaries of the health system about their perceptions of disease and health problems, and es‐
pecially about their priorities with regard to health related actions, can add an important ele‐
ment in the health planning cycle. Lengeler et al [71] observed that indirect health interview
represents a methodical evolution of the traditional interview approach by the fact that ques‐
tionnaires are not administered directly by the investigators or their field staff to the key inform‐
ants.  Rather,  they  are  distributed  through  an  existing  administrative  channel  and  self-
administered by the recipients. The school system is therefore the appropriate structure to base a
study on the prevalence of schistosomiasis. This is anchored on the fact that those who bear the
greatest burden of the disease can be easily reached through this channel. Additionally, schools
are widely cited and are very likely to be located in remote endemic areas. Thirdly, teachers are
competent enough with minimal training to carry out an exercise of this nature.
Several epidemiological studies are available in the literature that tested the usefulness of
this mode of diagnosis. Useh and Ejezie [72] worked on the “evaluation and validation of
the questionnaire approach for the diagnosis of urinary schistosomiasis in Biase Local Gov‐
ernment Area of Nigeria among school pupils”. The questionnaire which enquired whether
pupils had urinary schistosomiasis or blood in urine in the preceding month, was adminis‐
tered by class teachers to the pupils. Urines samples collected for the validation of the ques‐
tionnaire diagnosis was also examined using dipsticks (by teachers and the research team).
There was a strong positive correlation between the pupils’s knowledge of schistosomiasis
as a disease and the reported presence of blood in urine (r=0.96) although the later was a
better indicator of the disease. The questionnaire technique (blood in urine) gave a compara‐
ble sensitivity (85.8%), specificity (81.4%), positive and negative predictive values (96.6%
and 47.9%) to the dipstick test with values of 96.6%, 88.4%, 98% and 69.1% respectively.
Teachers were able to detect haematuria with a high degree of accuracy. We found this ap‐
proach to be simple, cost-effective and reliable and recommended its usage in other endemic
settings with large land mass and dense population like Nigeria (See Table 3).
Survey
Method
TP
a
FP
B
FN
C
TN
d
SENS
(%)
SPEC
(%)
PPV
(%)
NPV
(%)
VAL
(%)
BIAS
(%)
P
Value
Blood in Urine 229 9 38 35 85.8 81.4 96.6 47.9 83.3 88.8 P<0.001
Schistosomiasis 207 15 60 28 77.5 65.1 93.2 31.8 73.4 83.1 P<0.001
TDST 231 7 36 36 86.5 83.7 97.1 50.0 84.3 89.1 P<0.001
RDST 250 5 17 38 93.6 88.4 98.0 69.1 91.9 95.5 P<0.001
True Positives, TP were defined as those with ova in urine (n=267). Altogether 310 pupils were examined.
TN- True Negative, FP- False Positive, FN- False Negative
SENS- Sensitivity, SPEC – Specificity, PPV- Positive Predictive Value, NPV- Negative Predictive Value, TDST- Teachers Dip‐
stick Testing, RDST- Researchers Dipstick Testing.
Adopted from Useh and Ejezie, [72].
Table 3. Comparison of the performance of different survey methods in relation to parasitologically confirmed
diagnosis
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Elsewhere, self-administered questionnaires, distributed by existing administrative channels
to village party chairmen, head teachers and school children, showed good diagnostic per‐
formance for the qualitative assessment of urinary schistosomisasis endemicity. At a cost 34
times below that of the WHO-recommended parasitological screening strategy, the school
children’s questionnaire allowed the screening of 75 out of 77 schools of a rural Tanzanian
district in 6 weeks, and the exclusion of schools not at high risk for urinary schistosomiasis
with over 90% confidence. The head teacher and party chairmen questionnaires made it pos‐
sible to assess the perceived importance of a spectrum of diseases and symptoms, among
which was schistosomiasis. The priority rank of schistosomiasis control was strongly corre‐
lated with the prevalence rate of the disease in the community. The questionnaires also
looked at the prioritization of health among other community issues and thus contributed
important information for planning at the district level [73].
Using questionnaires facilitate immense savings in cost as well as reaching a vast land mass.
However, in areas of low school attendance, reliable information may not be collected. In‐
fected but unidentified school-age children that are out of school would invalidate control
efforts, as they would continuously contaminate water bodies. Other limitations as outlined
by Chitsulo et al [67] are-
• results obtained with school children may not always be typical for the whole community
especially if a lot of the children of this age are not in school or where one sex is badly
under-represented
• the methodology does not identify which child is infected. To obtain this information, a
second step using conventional diagnostic method would be necessary
• true prevalence is usually underestimated since the method relies on re-call as those who
are mildly infected may not recall having had haematuria
• in some countries, girls and boys may perceive the disease differently or give different an‐
swers to questions asked about it.
3.5. Immunodiagnosis
Immunodiagnositic methods are so far the only alternative to parasitological test. They al‐
low the demonstration of specific anti-schistosomal antibodies and to a certain extent, the
tracing of circulating antigens and/or immune complexes in sera of parasite carriers [36].
Wilkins et al [55] noted that they offer the most practical assays for epidemiological studies
and patient management. They are particularly valuable if the density of the parasites (or
their developmental stages) in a specimen is very low or if the biology of the parasite does
not allow its direct demonstration e.g localization of certain stages in internal organs.
Serological procedures such as immunodiffusion, complement fixation test, indirect hae‐
magglutination assay, immunoflourescent antibody assay have been used for the diagnosis
of schistosomiasis. Others include enzyme linked immunosorbent (ELISA), radioimmunoas‐
sy and radio-allegrosorbent assay among others. The relevance of antibody detection in the
diagnosis of schistosomiasis has been reviewed in great details by Hamilton et al [74]. They
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concluded that due to the relative insensitivity of both parasitology and antigen detection,
antibody detection methods could find increasing use in situations of low infection intensi‐
ty. The performance of antibody detection for the diagnosis of schistosomiasis has been test‐
ed in Kenya. Approximately 1500 blood samples from 3 areas with endemic schistosomiasis
and from a non-endemic control area, were tested for their antibody reactivity in ELISA. The
results were compared with infection status determined by parasitological examination.
Two test antigens were used ;unfractionated S. mansoni egg homogenate (SEA) and CEF6, a
partially purified fraction of SEA containing 2 cationic antigens. Blood from patients with S.
haematobium infection cross-reacted significantly with the two S. mansoni antigen prepara‐
tions, but reactivity against CEF6 appeared more specifically indicative of S. mansoni infec‐
tion. There was a significant positive correlation between blood ELISA results and the
number of eggs excreted by infected subjects in the area endemic for S. mansoni only. High‐
est correlation coefficients were obtained in children aged 10 years and CEF6 gave marginal‐
ly higher correlation coefficient than SEA. The graphs of prevalence and intensity of
schistosome infection drawn from the serological results were similar in shape to the graph
of these 2 quantities based on parasitological results, and the results indicate that serology
merits wider use as an epidemiological tool for determining infection status in schistosomia‐
sis [75]. In a different but related study, the relative concentration of IgM and IgG antibodies
to S. mansoni soluble egg antigen were evaluated in paired samples of venous blood, sera
and buffer elutes of capillary blood drops dried on filter papers [76]. The samples were ob‐
tained from school children at early and chronic stages of schistosomiasis diagnosed on the
basis of history, clinical symptomatology and parasitological criteria. ELISA simultaneously
performed, revealed paired samples to display comparable antibody levels in all cases. Sam‐
ples from children with early schistosomiasis had specific IgM : IgG ratios greater than 1 in
sera and blood elutes. This ratio, however was less than 1 in samples from chronically infect‐
ed children. The specific advantages of this simplified technique are the use of anti-SEA an‐
tibodies in finger-stick blood elutes, rather than sera or venous blood to serologically
diagnose schistosomiasis and to differentiate early from chronic infections particularly when
used for mass screening such as epidemiological surveys. Elsewhere, Mclaren et al [77]
showed that S. mansoni SEA gave a sensitivity of 92.3% in diagnosing S. haematobium infec‐
tion and 96.2% for S. mansoni and a specificity of 97.4% in ELISA. Recently, Chand et al [78]
reported on the development of a new assay for the diagnosis of schistosomiasis, using cer‐
carial antigens. They showed that the cercarial antigen assay was equivalent to the SEA as‐
say for serodiagnosis of schistosomiasis in a non-endemic setting. Since the cercarial
antigens is more easily obtained and prepared than SEA, the authors inferred this assay may
be preferred for routine clinical use and may be amenable for scaling up.
Although the application of serological tests has, without doubt, contributed to epidemio‐
logical surveys, such studies are of limited use because some of the tests lack reasonable lev‐
els of acceptable sensitivity and specificity or are technically difficult to be carried out in
field surveys. Other drawbacks as outlined by Weiland [36] are;
• inability to indicate the intensity of infection or differentiate active from chronic infection
• no correlation between morbidity and sero-reactivity
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• cross-reaction with antibodies to other helminthes including animal schistosomes
• unresolved seropositivity remain for years after treatment or after an infection has died out.
The greatest impediment hindering the utilization of immunodiagnosis in third world coun‐
tries particularly in Africa is lack of financial resources to procure the sophisticated equip‐
ment required to carry out some of these procedures and the training of skilled manpower
to handle them.
3.6. Rapid diagnostic test
The advent of rapid diagnostic tests has facilitated the immediate treatment of subjects with
infectious diseases in the field after diagnosis. Results are usually available within 30 mi‐
nutes compared to the conventional tests. Apart from its simplicity and ease of carrying out
devoid of technicality, the availability of electricity is not required. Rapid diagnostic tests
are being deployed in endemic countries for the identification of subjects with malaria, HIV
and hepatitis for prompt treatment. Encouraging reports are available in the literature on
the development of rapid diagnostic test for schistosomiasis. De jonge et al [79] developed a
reagent strip test for detection of circulating cathodic antigen in urine. In a related study,
Bosompem et al [80] showed that S. haematobium antigen complexed with complement C3
can be isolated from the urine of infected persons by using a mouse monoclonal antibody.
These investigators demonstrated that goat anti-human C3 would also detect schistosome
antigen/complement complex in urine of infected persons used as case-controls and subse‐
quently developed a monoclonal antibody dipstick test on the basis of these findings. How‐
ever, a lot of standardization would be required before these strips are approved by the
WHO and other regulatory organizations for deployment in endemic countries.
4. Control of schistosomiasis
The cardinal objective in the control of schistosomiasis is the reduction of morbidity and
mortality to levels below public health significance. Over the years, emphasis has shifted
from the non-realizable goal of eradication to the more realistic goal of morbidity control. In
this context, Gemmel et al [81], defined “a control programme” as the “implementation of
specific measures by a disease control authority to limit the incidence of the disease”. Such
implementation may involve specific technical interventions and perhaps legislation to en‐
force compliance. The success of this type of approach is predicated on an accurate ecologi‐
cal diagnosis, that is, a diagnosis of the human community, its parasitological
characteristics, its physico-geographical environmental attributes and man’s behavioural at‐
titudes and customs [82].
The enormous morbidity associated with schistosomiasis  which ranks it  next  to  malaria
in terms of public health significance re-emphasizes the need for a coordinated and sus‐
tainable  means  for  the  control  of  the  disease.  There  is  a  consensus  of  opinion  that  the
control  of  the  disease  should  be  integrated.  In  this  model  of  control,  King  [83]  identi‐
fied the applicable approaches as:
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• Population based chemotherapy
• Snail  control which involves habitat  modification and use of plant and chemical mol‐
luscicides,
• Proper treatment of sewage,
• Good environmental engineering designs for the development of irrigation and hydro‐
electric schemes to limit the availability of breeding grounds for the snail vectors
• Provision of clean and safe piped water and
• Massive  health  education  and  mobilization  of  the  population  to  claim  ownership  of
the programme
The WHO Expert Committee on Epidemiology and Control of Schistosomiasis took a holistic
approach at the control of the disease and noted that “comprehensive understanding of the envi‐
ronment, demographic, social, human behavioural and economic factors” in schistosomiasis is
essential for the design of control programmes that are successful in the long run [84]. With the
advent of praziquantel (PZQ) as a safe and efficacious drug for the treatment of schistosomiasis,
the WHO in 1991 reinforced its 1984 recommendation to shift from transmission control (focus‐
ing on the prevalence of infection) to morbidity control (laying emphasis on intensity of infec‐
tion) [8]. Morbidity control will not only reduce the number of people infected but it will also
drastically reduce environmental contamination with the eggs even when cure is not attained. A
drastic reduction of the pollution of the environment with the eggs would also reduce the chan‐
ces of transmission. Should this occur at a level below public health importance, the probability
of eventual elimination of disease is certain with a sustained integrated approach
4.1. Chemotherapeutic control of schistosomiasis
Of all the methods of control listed above, chemotherapy is the only one that is widely used
presently in endemic areas for the control of morbidity due to schistosomiasis. Among the
first group of drugs used for the treatment of schistosomiasis included; antimonials, nirida‐
zole, hycanthone, lucanthone, oxamniquine and albendazole. PZQ is currently used for the
treatment of all the species while metrifonate is active against S. haematobium only. Recently,
artemisinins earlier synthesized for the treatment of malaria infection is being used in some
endemic communities to treat schistosomiasis. The WHO [11] identified four approaches in
the administration of chemotherapy programme namely;
i. Mass treatment: treatment of the entire population. This is often limited by availa‐
bility of finance.
ii. Selective population treatment: treatment of infected persons identified by a diag‐
nostic survey of the whole population
iii. Selective group treatment: treatment of all or infected members of a high risk age
or occupational group
iv. Phased treatment: use of the above strategies in a sequence of progressively greater
selectivity.
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Only the chemotherapeutic form of control of schistosomiasis is covered in the present re‐
view. This does not in any way reduce the importance of the other methods. It has already
been emphasized above that the sustainable control of schistosomiasis involves the integra‐
tion of several methods listed above. A comprehensive review on the control of schistoso‐
miasis by this author can be found elsewhere [85]. In the next few paragraphs, the modes of
action of several drugs use for the treatment of schistosomiasis are examined.
4.1.1. Praziquantel (PZQ)
4.1.1.1. Biochemical properties and pharmacokinetics
Praziquantel (PZO) is the drug of choice for the treatment of schistosomiasis. It is a broad
spectrum anti-schistosomal which is principally active against the adult stage of all the
schistosome species infective to man. It is a 2-cyclohexycarbonyl 1,2,3,6,7,11b-hexahy‐
dro-4H-pyrazino(2,1-a Isoquinolin-4one) compound with a melting point at 136-140C. It was
developed in the laboratories for Parasitological Research of Bayer AG and Merck KGaA in
Germany (Elbert and Darmstadt) in the mid 1970s. It has a molecular mass of 312.411 with a
serum half life of 0.8 to 1.5 hours in adults with normal liver and kidney function and is
mainly excreted in urine. PZQ is a white crystalline powder with bitter taste. It is stable un‐
der normal storage conditions. Although, it is insoluble in water, it is soluble in chloroform,
dimethylsulfoxide and ethanol. It is sold as a racemate mixture consisting of equal parts of
‘laevo’ and ‘dextro’ isomers, of which only the laevo component displays anti-schistosomal
properties.
The recommended dose of PZO is 40 mg/kg body weight. The drug is available as a 600mg
tablet. The quality of PZQ (proprietary and generic) currently available in the market is
quite high and acceptable. Thirty four [34] PZQ samples from different manufacturers were
collected at the user level in various countries and subjected to quantitative analysis of ac‐
tive ingredient, purity, disintegration and dissolution in accordance with established phar‐
macopoeial standards. The results showed that most of the samples were of high quality
except two samples from the same manufacturer that had no PZQ [86]. About 90% of the
damage done to organ function is known to reverse six months following the administration
of PZQ. Although it is exceptionally well tolerated, reported side –effects include abdominal
discomfort, nausea, headache, dizziness, drowsiness and pyrexia especially in subjects with
high egg counts [87].
4.1.1.2. Mode of action of PZO
The mode of action of PZQ has been extensively reviewed elsewhere [88,89]. The exact
mechanisms of action of PZQ is still poorly understood. PZQ is known to induce rapid calci‐
um influx that distort the morhoplogy and physiology of schistosome. Jeziorski and Green‐
berg [90] showed that the B subunits of voltage-gated Ca2+ channels is the prime molecular
target of PZQ. It has recently been reported that cytochalasin D abolished the schistosomici‐
cidal activity of PZQ but calcium influx into PZQ exposed schistosomes was not halted. This
therefore raises doubts whether calcium influx is essential in the antischistosomal activity of
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PZQ [91]. PZQ induces contraction of schistosomes which manifest in paralysis in the con‐
tracted state. Additionally, vacuolation and blebbing near and on the surface of the worm
have equally been reported [92].
PZQ is known to increase exposure of antigens on the worm surface. It is believed that this
in turn renders the worm more susceptible to antibody attack. Doenhoff et al [93] inferred
that this drug induced antigen exposure is assumed to account for the synergistic effect be‐
tween PZQ and the host antibodies in killing worms invivo. Recently, it has been shown
that PZQ seems to interfere with adenosine uptake in cultured worms. This may have thera‐
peutical relevance given that the schistosome is unable to synthesize purines such as adeno‐
sine de novo. It may be assumed that the drug interferes with schistosome’s obligate need to
acquire adenosine from its host. This is confounding as a relationship between Ca2+ channels
and adenosine receptors has been demonstrated in cells of some other animals and adeno‐
sine can antagonize Ca2+ release. This informs the inference drawn by Angelucci et al [94]
that PZQ-induced Ca2+ influx and adenosine receptor blockade may be connected.
4.1.1.3. Oxamniquine – Molecular structure and pharmacokinetics
Oxamniquine  was  first  described  in  the  late  1960s.  The  compound is  6-hydromethyl-2-
isopropyl-aminomethyl-7-nitro  1,2,4-tetrahydroquinoline.  It  is  produced  by  biological
processes.  The  drug is  administered as  15mg/kg body weight  for  adults  while  children
are  treated  with  20mg/kg  given  in  two  doses  of  10mg/kg  each  in  an  interval  of  3-8
hours. It is extensively metabolised through oxidation process. The metabolites are active
and excreted  in  urine.  The  side  effects  are  mild,  transient  and well  tolerated  especially
when given after a meal [95].
4.1.1.4. Mode of action
Unlike PZQ, the mechanism of action of oxamniquine is fairly well understood. Oxamni‐
quine is only active against S. mansoni but not effective against S. haematobium and S. japoni‐
cum. The active ingredient is tetrahydroquinoline which acts on the adult S. mansoni and
immature invasive stages, with males more susceptible than the females. Its anticholinergic
effect, which increases parasite motility and inhibits nucleic acid synthesis, has no notable
effect on the other Schistosome species [96]. The mechanism of action of oxamniquine is relat‐
ed to irreversible inhibition of nucleic acid metabolism of the parasite. The drug is activated
in a single step, in which the Schistosoma enzyme converts the oxamniquine to an ester, and
spontaneously dissociates resulting in an electrophilic reactant and alkylation of the Schisto‐
soma DNA. Worm death is associated with the formation of sub-tegumental vesicules in
adult parasites. Different responses are observed after therapy, with less specific morpho‐
logical alteration and hepatic shifts, occurring over a period of six days post treatment [95].
4.1.1.5. Metrifonate
Metrifonate  was  initially  introduced  as  an  insecticide  in  1952,  but  later  in  1960,  it  was
used  to  treat  helminth  infection.  The  drug  also  refer  to  as  trichlorophone  is  a  organo‐
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phosphorus ester which is only active against S.haematobium.  It  is  rapidly absorbed, me‐
tabolized  and  excreted.  The  metabolic  pathway  yields  DDVP  (2,2-dichlorovinyl
dimethylphosphate), a cholin esterase inhibitor which is the active compound. The mech‐
anism of  action is  not  known.  It  is  relatively cheap and is  not  toxic.  Metrifonate  is  ad‐
ministered  as  7.5-10  mg/kg  body  weight,  given  in  three  divided  doses  in  two  weeks
interval.  Among  the  side  effects  reported  following  the  administration  of  the  drug  in‐
clude abdominal pains, diarrhoea, fatigue and muscular weakness which dissipates with‐
in 12 -24 hours [97].  The reasoning behind the widely spread dosage has to do with its
inhibitory effects on red cells and plasma cholinesterase.
Metrifonate is not currently used for the treatment of urinary schistosomiasis. Several rea‐
sons account for this. One of which is poor compliance by patients as a result of the spacing
and multiple dosing. The second reason is reduced level of efficacy. For instance, Mgeni et al
[98] reported a cure rate of 40% and egg reduction rate of 90% in Zanzibar. Lastly, the ad‐
vent of PZQ with its superior efficacy rate and broad spectrum activity meant that it was no
longer cost effective and sustainable to rely on metrifonate.
4.1.1.6. Artemisinin and its derivatives – Biochemical characteristics and pharmacokinetics
The artemisinins though syntheised for the treatment of malaria is the newest drug used for
the treatment of schistosomiasis. Unlike PZQ, which is active against the adult stages of the
parasite, artemisinin is active against the immature stage of parasite. It is a sequitterpene
lactone with a peroxide group, obtained from the leaves of the plant, Artemisia annua which
are grown in Central Europe, China, USA and Argentina among others. The major deriva‐
tives of artemisinin are artesunate, artemether, arteether with dihydroartemisinin as the
principal active metabolite. Primarily they are antimalarials, but the anti-schistosomal prop‐
erties were discovered by Chinese scientists in the 1980s especially for the treatment of S ja‐
ponicum infection [99]. They are well tolerated with only minor side effects.
4.1.1.7. Mode of action of artemisinin
The precise mode of action of this drug is not known. Artemether is the most potent. It ex‐
hibits the highest level of activity on one to three weeks old liver stages of the parasite.
When a dosage of 6mg/kg weight is administered, it kills the schistosomulas during the first
21 days. The invasive and adult stages are less affected and the adult females are more sus‐
ceptible than the males [100]. Following treatment, artemether induces severe and extensive
tegumental damage and significant reduction in glycogen contents through the inhibition of
glycolsis, but the onset of this alteration is slow. It also hinders the development of egg lay‐
ing adult worm pairs [101].
PZQ is currently the drug of choice for the treatment of all forms of the disease. It is safe and
well tolerated. Readers are referred to a very detailed review on “praziquantel: its use in
control of control of schistosomiasis in sub-Saharan Africa and current research needs [89]
and “praziquantel: mechanisms of action, resistance and new derivatives for schistosomia‐
sis” [88]. Elsewhere, we reported on the high efficacy and tolerability of PZQ [102] and arte‐
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sunate [103] for the treatment of urinary schistosomiasis in Nigeria.These authors noted that
despite the fact that PZQ is being widely used, there is no clinically relevant evidence for
resistance to date, but worrying low-cure rates have been recorded in some studies. They
also observed that there is also no assurance that PZQ and/or Schistosomes are in any way
unique and that resistant organisms will not be selected as a result of widespread usage. Ar‐
tesiminis and the related 1,2,4-trioxolanes are now promising antischistosomal compounds,
as are inhibitors of a schistosome-specific bifunctional enzyme, thioredoxin-glutathione re‐
ductase. In some endemic communities, artesunate is also used for the treatment of malaria
singly or in combination. Therefore, where artesunate is used for the treatment of urinary
schistosomiasis, resistance may likely develop to malaria. It is pertinent to do an analysis on
why schistosomiasis is still highly endemic in some parts of Africa including Nigeria when a
potent drug is available for the management of the disorder.
4.1.1.8. Impediments of control of schistosomiais
Several factors are responsible for the continuing endemicity of schistosomiasis in Africa.
Some of the factors are examined below;
4.1.1.8.1. High cost of PZQ
Richards [104] identified community-based annual mass drug administration with safe and
effective oral drugs as the principal strategy for the control of onchocerciasis, lymphatic fi‐
lariasis and schistosomiasis. It has been demonstrated that annual treatments with the mi‐
crofilaricide ivermectin (Mectizan, donated by Merck &Co., Inc.) prevents severe eye disease
and skin manifestations of onchocerciasis while the transmission of LF by mosquitoes can be
interrupted in Africa by annual single-dose combination therapy with ivermectin and alben‐
dazole (donated by GlaxoSmithKline) [105]. Mass distribution of PZQ can significantly re‐
duce schistosomiasis morbidity [106]. However, unlike ivermectin and albendazole, PZQ is
not donated and costs approximately US $0.20. Schistosomiasis is a disease that affects poor
rural agricultural workers who in most cases cannot afford the cost of PZQ. This is one of
the greatest impediments in the control of the disease.
4.1.1.8.2. Lack of political commitment and provision of finance
Until  recently,  there  was no sustained political  and financial  commitment  by the  WHO
and  her  health-related  agencies  and  governments  of  schistosomiasis  endemic  countries
towards the control of schistosomiasis. The success story reported in the control of schis‐
tosomiasis in Brazil, China, Egypt, Laos and the Philippines [10,107,108] is an encourage‐
ment that the disease can be controlled when the right programmes and processes are in
place.  Over the years,  emphasis  on funding of  infectious disease control  was placed on
HIV/AIDS, malaria and tuberculosis/leprosy. That informed the categorization of schisto‐
somiasis  as  one of  the neglected tropical  diseases.  However,  the situation changed dur‐
ing  the  54th  World  Health  Assembly  held  in  May,  2001  where  resolution  WHA  54.19
namely  that  at  least  75%  of  school-age  children  in  the  high-burden  regions  should  be
treated regularly  with  PZQ.  This  was  further  enhanced by the  launch of  the  Schistoso‐
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miasis Control Initiative [SCI] supported by a US$ 30 million grant from the Bill and Me‐
lina Gates Foundation. The SCI is a partnership between Imperial College, London, UK;
the  Seattle-based  Gates  Foundation,  WHO,  Geneva;  Harvard  School  of  Public  Health,
Boston  and high-burden  country  representatives.  This  renewed interest  has  encouraged
the Carter Centre to be involved in the control of schistosomiasis in Nigeria. The Centre
is  assisting  in  the  control  of  schistosomiasis  in  three  states  namely;  Plateau,  Nasarawa
and Delta. The Centre is doing this by using the grassroots distribution system of health
workers  and  village  volunteers  for  onchocerciasis  to  also  deliver  health  education  and
conduct  mass  drug  administration  with  PZQ  annually  in  areas  affected  by  both  para‐
sites. Since 1999, this programme has delivered a cumulative total of 1,079,335 treatments
with PZQ. Studies in a sample of villages in two areas showed a reduction in prevalence
of  bloody  urine  assessed  by  dipsticks  from  47%  in  1999  to  8%  in  2002,  after  just  two
years of  annual treatments [109].  This success means that LF,  onchoceriasis  and schisto‐
somiasis  can be  treated by community  health  workers  at  the  same time thereby saving
enormous cost as a recent clinical trial  in Thailand found no clinically relevant pharma‐
cokinetic changes or adverse reactions when ivermectin, PZQ and albendazole were giv‐
en concurrently [110]
4.1.1.8.3. Lack of strong health system
The health system of many countries in the developing world are not synchronized and in‐
tegrated. This renders the delivery of health packages difficult and cumbersome. However,
there is a conseneus that strong, well integrated and effective health systems are essentials
to reduce disease burden and to achieving the health related MDGs. A Strong health sys‐
tems typically consist of seven building blocks [111,112]. These include: service delivery,
governance structures, financial mechanisms, human resources, medicines and technology
supply system, health information system and participatory community mechanisms (peo‐
ple). In an ideal situation, these seven components must exist and work together to generate
quality (accessible, equitable, responsive health care)
4.1.1.8.4. Health failures
Failures associated with the planning and delivery of healthcare are critical issues that
should be targeted to ensure success in the control of infectious diseases including schisto‐
soimasis. In this context, Mahoney and Morel [113] argued that innovation disparity has cre‐
ated 3 kinds of “health failures” namely “science failure, market failure and public health
failure”. Science failure refers “to a lack of knowledge and tools to address health problems
e.g there are still no effective vaccines or drugs for schistosomiasis”. Market failures happen
“when stock-outs occur due to high demand or when the purchase costs of drugs, vaccines
and health interventions prevent the poor from accessing them”. Often the new drugs and
diagnostics are very expensive to develop and /or require sophisticated technical and health
infrastructure for optimal use. Public health failure arises “due to lack of good governance,
transparency and effective delivery systems and a clear articulation of priorities and val‐
ues”. Political and economic instability, cultural and religious barriers and shift in govern‐
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ment priorities can block the uptake and implementation of health innovations. This is
particularly true in Africa where frequent changes of government and dislocation of com‐
munities as a result of natural disasters and inter and intra-tribal wars have contributed to
hinder outcome of disease control programmes.
5. Development of a schistosome vaccine
Despite  the existence of  effective chemotherapeutic  agents,  progress  towards controlling
schistosomiasis  has  been  slow.  Additionally,  the  possible  development  of  resistance  to
PZQ  and  other  compounds,  rapid  re-infection  and  the  overall  economic  cost,  demand
that  other  approaches  be  pursued [114].  Butterworth  et  al  [115]  argued that  the  aim of
vaccination  is  to  reduce  morbidity.  As  in  the  various  animal  models,  immunity  in  hu‐
mans  appears  to  be  frequently  incomplete.  “Immune” adults  often  do become infected,
but  at  lower  intensities  than  “susceptible”  children.  Several  investigations  have  con‐
firmed that  the  severity  of  clinical  disease  is  dependent  on intensity  of  infection rather
than simply the presence or absence of infection [116,117] implying that even an incom‐
plete immunity may be of considerable value.
An excellent review on the search for a schistosome vaccine was published not too long ago
[118]. These authors rightly chronicled the search for the discovery of candidate vaccine
molecules to have transited through mining crude extracts, monoclonal antibody targets, an‐
ti-idiotypes, expression library screening and immunogenicity. The early disappointment
that was recorded with the vaccination of mice with crude worm extracts or purified compo‐
nents, followed by cercarial challenge [119,120] and utilizing the idea of concomitant im‐
munity [121] were equally reviewed. Wilson and Coulson [118] concluded that the
sequencing of S. mansoni transriptome and genome and the development of proteomic and
microarray technologies has drastically improved the possibilities for identiflying novel vac‐
cine candidates, particularly proteins secreted from or exposed at the surface of schistoso‐
mula and adult worms. The parameters of an attenuated schistosome vaccine has been
evaluated in the Olive Baboon [122]. Five exposures of baboons to the attenuated schisto‐
some vaccine gave greater protection than three exposures, but this attenuation was not sus‐
tained when challenge was delayed. Within the scope of the data collected, faecal and
circulating antigen levels did not accurately predict the observed worm burdens. Levels of
immunoglobulin G at challenge correlated best with protection, but there was little evidence
of a recall response. In a related study in baboons, Coulson and Kariuki [123] showed that
neither a preceding infection, terminated by chemotherapy, nor an ongoing chronic infec‐
tion affected the level of protection. Whilst IgM responses to vaccination or infection were
short-lived, IgG responses rose with each successive exposure to vaccine.
The greatest hope for the discovery of a schistosome vaccine lies in Sh28GST which has al‐
ready undergone Phases 1 and 2 human trials [124]. No adverse side effects were recorded
in human recipients and high titres of antibodies were elicited in Phase 1 and phase 2 trials
[125]. The results of phase 3 human trials is being awaited. As noted by Curwen et al [126]
Parasitic Diseases - Schistosomiasis82
and Dillion et al [127], current advances in post-genomic techniques are providing new ave‐
nues and hope to identify the secreted and surface-exposed antigens that mediate protec‐
tion. The search must be sustained as vaccination is the most cost-effective and sustainable
means of controlling endemic infectious diseases.
6. Conclusion
Schistosomiasis  is  still  endemic  in  many  parts  of  Africa  particularly  Nigeria.  Activities
related  to  electric  power  development/generation  and  agriculture  have  extended  areas
of endemicity just as new foci of infection are being described. The control of schistoso‐
miasis  requires  an  integrated  process.  However,  chemotherapy  with  PZQ  is  the  main‐
stay  for  the  control  of  the  disease  in  the  short-term.  Poverty  on  the  part  of  infected
subjects,  lack  of  deployment  of  political  and  financial  resources  by  disease  endemic
countries  are  the  major  factors  limiting the  control  of  the  disease.  The  global  economic
recession has contributed in reducing financial  resources available through bilateral  and
multilateral avenues for the control of the infectious diseases just as increase in interna‐
tional  travels  and  tourism  have  led  to  the  reporting  of  “imported  schistosomiasis”  in
non-endemic countries.
Recommendation
The following recommendations are suggested for the control of schistosomiasis;
• Governments of disease endemic countries should show serious political and financial
commitment towards the control of schistosomiasis. Overall, the health sector should be
funded in line with the recommendation of the WHO.
• Pharmaceutical companies should be encourage to donate PZQ free as is obtainable with
albendazole and ivermectin or in the alternative reduce the cost of the drug.
• The delivery of PZQ should be integrated into ongoing programme of distribution of
ivermectin and albendazole by community health workers as it has been shown that tak‐
ing the three drugs concurrently is safe and effective
• There should be a deliberate policy of providing piped water in endemic communities to
reduce the chances of coming in contact with cercariae infested water bodies
• Researchers should be encouraged to develop rapid diagnostic and cost-effective test
based on antibody detection which can provide results within 15-20 minutes in the field
for the diagnosis of schistomiasis and instant treatment.
• More researches are required to hasten the development of a vaccine for schistosomiasis.
This is the only means of long term control of this disease.
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